The Receptor Argument: Can Modern Psychedelic Science Read the Rigveda?

The soma debate ran for a century on philology and botany. In the last two decades a third discipline arrived uninvited: a clinical literature reporting that one pharmacological class — the serotonergic psychedelics — occasions experiences their subjects describe in the vocabulary the hymns use. This spine maps an essay about that arrival. Its question is not what soma was; the batch’s candidacy spine audits the plants. Its question is whether a modern receptor pharmacology can constrain a Bronze Age identification at all, and under what rules.

I. The New Witness

The essay opens by stating what changed. The older debate matched plants to verses; the new literature matches drug classes to experience types, under controlled conditions, with validated instruments. This section reports that literature as it stands — mystical-type experience occasioned at high rates by serotonergic compounds in the published trials, with the correlations the field reports flagged for the claims register — and states why it is a genuinely new kind of witness rather than a rerun of the old enthusiasm.

II. The Inference Being Offered

The essay then makes the implicit argument explicit, because it is usually left as an insinuation: the hymns describe an experience type; one drug class reliably produces that type; therefore the sacrament belonged to that class. Stated plainly, the syllogism shows its joints — and the section names each: whether the hymns describe experience at all, whether experience types survive translation across three millennia, and whether reliability in a trial says anything about identity in a ritual.

III. The Set-and-Setting Objection

The strongest internal check comes from the psychedelic literature itself. Its founding doctrine holds that drug effects are shaped by expectation and context — which cuts against any inference from modern trial phenomenology to ancient ritual phenomenology. If the same molecule produces different experiences in different worlds, the experience described in the hymns underdetermines the molecule. The essay states this objection at full strength and asks what, if anything, survives it.

IV. The Comparative Phenomenology Test

What would a disciplined version of the inference look like? This section designs it: a coding of the hymns’ effect vocabulary done blind to any candidate, set against the validated questionnaires’ item structure, with the mismatches reported as prominently as the matches. The section also names the confound the essay must not bury — the hymns are liturgy, composed for performance, and a genre is not a trip report.

V. What the Receptor Cannot Testify To

The boundary section. Receptor pharmacology can, at most, sort candidate classes by their capacity to produce what the text appears to describe. It cannot recover preparation, dosage, adulterants, or the ritual’s management of the experience — and the standard literature’s leading non-psychedelic candidate wins precisely on those grounds the receptor cannot see. The essay concedes the asymmetry openly: the stimulant case rests on ritual mechanics, the psychedelic case on experience, and the two kinds of evidence do not currently meet.

VI. The Verdict Structure

The closing section fixes what the finished essay may conclude. Strongest available: the clinical literature licenses a ranking of experience-compatibility among candidates, nothing more. Weakest acceptable: the literature is inadmissible across the historical distance, and the essay must say so if the method fails its own tests. Either way, the contribution is the rules — the soma file gains a standard for what neuroscience testimony is worth in it.

Counter-case

The strongest opposing view holds that the entire enterprise is anachronism with instruments. Vedicists have long argued that the hymns’ exhilaration reads as alertness and inspiration, not vision — the stimulant profile — and that the visionary reading was always a projection of the modern psychedelic imagination onto a text that resists it. The clinical literature itself is young, its mystical-experience instruments contested, its trial populations unrepresentative of anything ancient. And the inference pattern — our drug produces experiences like your scripture describes, therefore your scripture describes our drug — is the exact structure of the entheogenic genre’s documented failures. The essay must grant that this view may simply be correct, and must be written so that its own method section survives even a null verdict.

Sources to verify

• The Rigveda’s soma hymns in independent scholarly translations, with attention to the effect vocabulary — UNVERIFIED, confirm before citing in the finished essay
• Griffiths and colleagues, the psilocybin mystical-experience trials at Johns Hopkins — UNVERIFIED, confirm before citing in the finished essay
• The validated mystical-experience questionnaire literature and its critics — UNVERIFIED, confirm before citing in the finished essay
• John Brough’s philological case against the visionary reading of soma — UNVERIFIED, confirm before citing in the finished essay
• Harry Falk on soma as stimulant — UNVERIFIED, confirm before citing in the finished essay
• Ido Hartogsohn, American Trip, on set and setting as constitutive of drug effects — UNVERIFIED, confirm before citing in the finished essay
• Review literature on serotonergic psychedelic pharmacology and receptor mechanisms — UNVERIFIED, confirm before citing in the finished essay

Stakes

The Institute’s soma file now runs on four axes — candidacy, historiography, calendar, and epithet — and this essay adds the fifth and most modern: the admissibility rules for scientific testimony about scripture. The entheogen thread’s credibility depends on refusing exactly the shortcut this essay examines. If the receptor argument can be disciplined, the file gains an instrument; if it cannot, the file gains a boundary — and the Institute’s method is better served by the boundary than by another enthusiastic identification.